Relaxin Stimulates Leukocyte Adhesion and Migration through a Relaxin Receptor LGR7-dependent Mechanism*
- ‡Genetics Program and ¶Department of Surgery, University of British Columbia and §The Prostate Centre, Vancouver General Hospital, Vancouver, British Columbia V6H 3Z6, Canada
- 1 To whom correspondence should be addressed: The Prostate Centre, Vancouver General Hospital, 2660 Oak St, Vancouver BC, V6H 3Z6, Canada. Tel.: 604-875-4818; Fax: 604-875-5654; E-mail: michael.cox{at}vch.ca.
Abstract
Leukocytes are critical effectors of inflammation and tumor biology. Chemokine-like factors produced by such inflammatory sites are key mediators of tumor growth that activate leukocytic recruitment and tumor infiltration and suppress immune surveillance. Here we report that the endocrine peptide hormone, relaxin, is a regulator of leukocyte biology with properties important in recruitment to sites of inflammation. This study uses the human monocytic cell line THP-1 and normal human peripheral blood mononuclear cells to define a novel role for relaxin in regulation of leukocyte adhesion and migration. Our studies indicate that relaxin promotes adenylate cyclase activation, substrate adhesion, and migratory capacity of mononuclear leukocytes through a relaxin receptor LGR7-dependent mechanism. Relaxin-stimulated cAMP accumulation was observed to occur primarily in non-adherent cells. Relaxin stimulation results in increased substrate adhesion and increased migratory activity of leukocytes. In addition, relaxin-stimulated substrate adhesion resulted in enhanced chemotaxis to monocyte chemoattractant protein-1. These responses in THP-1 and peripheral blood mononuclear cells are relaxin dose-dependent and proportional to cAMP accumulation. We further demonstrate that LGR7 is critical for mediating these biological responses by use of RNA interference lentiviral short hairpin constructs. In summary, we provide evidence that relaxin is a novel leukocyte stimulatory agent with properties affecting adhesion and chemomigration.
Footnotes
-
↵2 The abbreviations used are: MCP-1, monocyte chemoattractant protein 1; PBMC, peripheral blood mononuclear cells; RLXH, histidine6-tagged recombinant human H2 relaxin; FSK, forskolin; IBMX, isobutylmethylxanthine; TBP, TATA-binding protein; PMA, phorbol 12-myristate 13-acetate; GF109203X, broad spectrum protein kinase C inhibitor; shRNA, short hairpin interfering RNA.
-
↵* This work was supported by operating grants from the National Cancer Institute of Canada and fellowship support from the Canadian Prostate Cancer Research Initiative (to K. A. F.) and the Michael Smith Foundation for Health Research (to M. E. C. and C. C. N.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
-
↵
The on-line version of this article (available at http://www.jbc.org) contains supplemental Fig. 1.
-
- Received June 20, 2005.
- Revision received October 20, 2005.
- The American Society for Biochemistry and Molecular Biology, Inc.











